NO20085412L - Pyrrolidinderivater som har aktivitet ved GLYT1 transportoren - Google Patents

Pyrrolidinderivater som har aktivitet ved GLYT1 transportoren

Info

Publication number
NO20085412L
NO20085412L NO20085412A NO20085412A NO20085412L NO 20085412 L NO20085412 L NO 20085412L NO 20085412 A NO20085412 A NO 20085412A NO 20085412 A NO20085412 A NO 20085412A NO 20085412 L NO20085412 L NO 20085412L
Authority
NO
Norway
Prior art keywords
activity
pyrrolidine derivatives
glyt1 transporter
glyt1
transporter
Prior art date
Application number
NO20085412A
Other languages
English (en)
Inventor
Leanda Jane Kindon
Claire L Anderton
David Clapman
Trevor Raymond Keel
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20085412L publication Critical patent/NO20085412L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Suksinat og napadisylatsaltene og solvatene av 2-[metyloksy)-A^-[metyl-l-fenyl-2-(l-pyrrolidinyl)propyl]-4,6-bis(trifluormetyl)benzamidrbis(trifluormetyl)benzamid napadisylat, og anvendelser derav ved behandling av forstyrrelser relatert til GlyTl transporter, slik som schizofreni, er beskrevet.
NO20085412A 2006-06-22 2008-12-30 Pyrrolidinderivater som har aktivitet ved GLYT1 transportoren NO20085412L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612420.0A GB0612420D0 (en) 2006-06-22 2006-06-22 Compounds
PCT/EP2007/056106 WO2007147831A1 (en) 2006-06-22 2007-06-20 Pyrrolidine derivatives having activity at the glyt1 transporter

Publications (1)

Publication Number Publication Date
NO20085412L true NO20085412L (no) 2009-01-22

Family

ID=36803732

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085412A NO20085412L (no) 2006-06-22 2008-12-30 Pyrrolidinderivater som har aktivitet ved GLYT1 transportoren

Country Status (23)

Country Link
US (1) US20080070973A1 (no)
EP (1) EP2041082B1 (no)
JP (1) JP2009541261A (no)
KR (1) KR20090019847A (no)
CN (1) CN101506156A (no)
AR (1) AR061554A1 (no)
AT (1) ATE444288T1 (no)
AU (1) AU2007263058A1 (no)
BR (1) BRPI0713311A2 (no)
CA (1) CA2655399A1 (no)
CL (1) CL2007001808A1 (no)
CR (1) CR10498A (no)
DE (1) DE602007002642D1 (no)
EA (1) EA200970044A1 (no)
ES (1) ES2333918T3 (no)
GB (1) GB0612420D0 (no)
IL (1) IL195633A0 (no)
MA (1) MA30522B1 (no)
NO (1) NO20085412L (no)
PE (1) PE20080380A1 (no)
TW (1) TW200817322A (no)
WO (1) WO2007147831A1 (no)
ZA (1) ZA200810009B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
US20100184996A1 (en) * 2007-06-20 2010-07-22 Glaxo Group Limited Process of amide formation
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
KR20200071090A (ko) 2017-10-13 2020-06-18 트리웨이 티더블유001 비.브이. 에다라본 염

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746959A (en) * 1953-06-02 1956-05-22 American Home Prod Diphenylethylenediamine-penicillin salt
US3145209A (en) * 1961-07-31 1964-08-18 Olin Mathieson Substituted aminophenyl-ethylamine derivatives
NZ237443A (en) * 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina

Also Published As

Publication number Publication date
IL195633A0 (en) 2009-09-01
CL2007001808A1 (es) 2008-01-18
AR061554A1 (es) 2008-09-03
KR20090019847A (ko) 2009-02-25
PE20080380A1 (es) 2008-05-31
ES2333918T3 (es) 2010-03-02
CR10498A (es) 2009-03-20
EP2041082A1 (en) 2009-04-01
CN101506156A (zh) 2009-08-12
JP2009541261A (ja) 2009-11-26
BRPI0713311A2 (pt) 2012-03-06
WO2007147831A1 (en) 2007-12-27
AU2007263058A1 (en) 2007-12-27
EA200970044A1 (ru) 2009-04-28
ATE444288T1 (de) 2009-10-15
TW200817322A (en) 2008-04-16
CA2655399A1 (en) 2007-12-27
MA30522B1 (fr) 2009-06-01
DE602007002642D1 (de) 2009-11-12
GB0612420D0 (en) 2006-08-02
US20080070973A1 (en) 2008-03-20
ZA200810009B (en) 2009-11-25
EP2041082B1 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
NO20090628L (no) Pyridizinon derivativater
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
NO20081838L (no) 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer
WO2007078815A3 (en) Certain chemical entities, compositions, and methods
WO2007089336A3 (en) Certain chemical entities, compositions and methods
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20070257L (no) Forbindelser, blandinger og metoder
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
WO2007070683A3 (en) Certain chemical entities, compositions and methods
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20090202L (no) Prolylhydroksylaseinhibitorer
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
NO20081042L (no) PPAR aktive forbindelser
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
EA201100266A1 (ru) Диокса-бицикло[3.2.1]октан-2,3,4-триольные производные
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
NO20070067L (no) Pyrrolopyridinderivater
EA200802329A1 (ru) Производные триазола ii

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application